Bone Diseases: Clinical Trials

446 trials for Bone Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

446 completed. 446 Phase 2, 62 Phase 1, 42 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2446Completed 446
Phase 162Completed 62
Phase 342Completed 42

Follow Bone Diseases: new trials by email Literature Review of Bone Diseases trials Research Report on Bone Diseases

Trials (filtered) newest first · largest first

All 446 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Effect of Oxytocin Nasal Spray on Preventing Postoperative Delirium in Elderly Patients Undergoing Orthopedic Surgery
oxytocin nasal spray - Cervical Spinal Stenosis, Thoracic Spinal Stenosis
Phase 2CompletedZhejiang University2272025-06-012026-08-20
Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma
intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar) - Osteosarcoma, Bone Cancer
Phase 1 / Phase 2CompletedShanghai 6th People's Hospital102024-12-032025-12-29
SB: Promoting Bone Health in Women
Multicomponent Exercise - Osteoporosis
Phase 1 / Phase 2CompletedInstituto Politécnico de Bragança402024-10-012025-05-06
Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial
Metformin Hydrochloride, betamethasone dipropionate, Pentoxifylline - Oral Submucous Fibrosis
Phase 1 / Phase 2CompletedZiauddin University302024-08-122025-05-02
Erector Spinae Plane Block vs Local Infiltration Following Fusion Surgery
Erector Spinae Block, Local infiltration with local anesthetic - Postoperative Delirium, Pain, Postoperative
Phase 2CompletedRashmi Mueller292024-05-152026-02-13
A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patients With Acromegaly
SYHX2008, Sandostatin LAR - Acromegaly
Phase 2CompletedCSPC ZhongQi Pharmaceutical Technology Co., Ltd.782024-04-162026-09-11
A Clinical Study of JS005 in Patients With Ankylosing Spondylitis
Recombinant humanized IL-17A Monoclonal Antibody(JS005), Placebo(JS005) - Ankylosing Spondylitis
Phase 2CompletedShanghai Junshi Bioscience Co., Ltd.2652024-01-132026-07-20
Senolytics to Improve Osteoporosis Therapy
Dasatinib 100 Mg Oral Tablet, Quercetin 1.250 mg (oral), Nicotinamide Riboside 1g (oral) - Osteopenia, Osteoporosis, Age-related Bone Loss
Phase 2CompletedOdense University Hospital1202023-09-062026-10-23
Fluorescence Imaging With Indocyanine Green(ICG) in Endoscopic Spinal Surgery
Indocyanine Green, Fluorescence imaging - Disc Herniation
Phase 1 / Phase 2CompletedZhongnan Hospital402023-04-112025-12-19
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia
Navepegritide (TransCon CNP), Placebo for Navepegritide (TransCon CNP) - Achondroplasia
Phase 2 / Phase 3CompletedAscendis Pharma Growth Disorders A/S842023-03-032026-07-14
Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis
Sonelokimab, Placebo, Adalimumab - Arthritis, Psoriatic
Phase 2CompletedMoonLake Immunotherapeutics AG2072022-12-132026-09-10
Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia
Burosumab - Fibrous Dysplasia Of Bone
Phase 2CompletedNational Institute of Dental and Craniofacial Research (NIDCR)122022-12-072026-02-02
Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia
denosumab - Fibrous Dysplasia
Phase 2CompletedNational Institute of Dental and Craniofacial Research (NIDCR)152022-10-122026-01-20
MAGnesium Effect With ANtiosteoporotic Drugs
Follow-up of patients with postmenopausal osteoporosis, with or without fractures, requiring initiation of injectable bisphosphonate therapy as part of their usual care, Follow-up of patients with postmenopausal osteoporosis, fractured or not, requiring initiation of injectable bisphosphonate therapy as part of care with magnesium supplementation - Osteoporosis, Postmenopausal
Phase 2CompletedUniversity Hospital, Clermont-Ferrand452022-06-282026-11-17
Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).
Bintrafusp alfa/M7824, Ibuprofen, PET scan - Olfactory Neuroblastoma, Esthesioneuroblastoma
Phase 2CompletedNational Cancer Institute (NCI)112022-06-212025-08-08
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration
Pemigatinib - Non-Small Cell Lung Cancer (NSCLC)
Phase 2CompletedIncyte Corporation82022-04-292025-08-05
Regorafenib in Patients With Refractory Primary Bone Tumors
Regorafenib - Osteosarcoma, Ewing Sarcoma of Bone
Phase 1 / Phase 2CompletedInstitute of Mother and Child, Warsaw, Poland302022-04-282026-10-07
Effectiveness of Vitamin C Supplementation in Treatment of Rickets
Vit C - Nutritional Rickets, Bone Turnover Rate Disorder
Phase 2 / Phase 3CompletedCairo University882022-03-012023-03-08
Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)
LUM-201 - Growth Hormone Deficiency
Phase 2CompletedLumos Pharma152022-02-182026-05-15
A Trial of YPEG-rhGH in Children With Short Stature
YPEG-rhGH, rhGH - Idiopathic Short Stature, Small for Gestational Age
Phase 2CompletedXiamen Amoytop Biotech Co., Ltd.782022-02-152024-01-24

Showing 20 of 446. Sign in to see all of them.

Narrower conditions

Osteoporosis (119)  ·  Bone Diseases, Metabolic (47)  ·  Arthritis, Psoriatic (33)  ·  Spondylitis, Ankylosing (30)  ·  Dwarfism, Pituitary (26)  ·  Osteoporosis, Postmenopausal (21)  ·  Acromegaly (19)  ·  Bone Neoplasms (19)  ·  Intervertebral Disc Degeneration (18)  ·  Dwarfism (17)  ·  Alveolar Bone Loss (12)  ·  Basal Cell Nevus Syndrome (12)  ·  Fractures, Bone (11)  ·  Musculoskeletal Diseases (11)

Broader conditions

Musculoskeletal Diseases (435)  ·  Nutritional and Metabolic Diseases (177)  ·  Metabolic Diseases (175)  ·  Bone Diseases, Metabolic (121)  ·  Spinal Diseases (106)  ·  Bone Diseases, Developmental (93)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (87)  ·  Endocrine System Diseases (80)  ·  Genetic Diseases, Inborn (72)  ·  Nervous System Diseases (72)  ·  Pathological Conditions, Signs and Symptoms (72)  ·  Joint Diseases (68)  ·  Arthritis (61)  ·  Skin and Connective Tissue Diseases (61)

Interventions

Alendronate (23)  ·  Teriparatide (18)  ·  Zoledronic Acid (17)  ·  Cholecalciferol (15)  ·  Denosumab (14)  ·  Human Growth Hormone (13)  ·  Calcium (12)  ·  Calcium Carbonate (10)  ·  Vitamin D (9)  ·  Growth Hormone (8)  ·  Parathyroid Hormone (8)  ·  burosumab (7)  ·  Octreotide (6)  ·  asfotase alfa (6)  ·  Cyclophosphamide (5)

Sponsors

Novartis Pharmaceuticals (14)  ·  Amgen (10)  ·  Massachusetts General Hospital (9)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (8)  ·  Alexion Pharmaceuticals, Inc. (6)  ·  Columbia University (6)  ·  Merck Sharp & Dohme LLC (6)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (6)  ·  AbbVie (5)  ·  Eli Lilly and Company (5)  ·  Mesoblast, Ltd. (5)  ·  Northwestern University (5)  ·  Children's Hospital Medical Center, Cincinnati (4)  ·  DePuy Spine (4)  ·  Masonic Cancer Center, University of Minnesota (4)

Countries

United States (225)  ·  Germany (52)  ·  United Kingdom (41)  ·  Poland (38)  ·  Canada (36)  ·  Spain (36)  ·  France (32)  ·  Italy (30)  ·  Hungary (29)  ·  Czechia (26)  ·  Australia (25)  ·  China (24)  ·  Russia (23)  ·  Denmark (20)  ·  Netherlands (19)

Top investigators

Ervin Epstein, MD (5)  ·  Elizabeth Shane, MD (4)  ·  Roger Brown (4)  ·  Thomas J Schnitzer, MD, PhD (4)  ·  Adi Cohen, MD (3)

Results publications

PMID 40194794, PMID 41807031, PMID 26529632, PMID 32417537, PMID 32762706, PMID 12795371, PMID 25769789, PMID 25919461, PMID 27699270, PMID 30334093, PMID 32721016, PMID 35789257, PMID 35833532, PMID 35931879, PMID 36178584, PMID 36792844, PMID 38649657, PMID 39151033, PMID 39890205, PMID 40576086, PMID 10976589, PMID 12877751, PMID 14500804, PMID 14695734, PMID 14988471, PMID 15674306, PMID 15722593, PMID 15883634, PMID 16076940, PMID 16087995, PMID 16093464, PMID 16231283, PMID 16430773, PMID 16449339, PMID 16495394, PMID 16996315, PMID 17116511, PMID 17164314, PMID 17192294, PMID 17333451, PMID 17577003, PMID 17592924, PMID 17708711, PMID 17763894, PMID 17904460, PMID 17911175, PMID 18053120, PMID 18397701, PMID 18456219, PMID 18495508

NIH funding

2016 (8), 2008 (5), 2015 (5), 2017 (5), 2018 (5), 2014 (4), 2019 (4), 2009 (3), P50AT000090 (3), 2005 (2), P50AR044855 (2), R01CA109584 (2), 1UL1RR025758 (1), 2004 (1), K08CA250418 (1)